The AHA released a new edition of the COVID-19 Snapshot, highlighting the critical needs of hospitals and health systems during the deepening public health emergency.
Novel Coronavirus (COVID-19) News
Below are links to AHA Today stories on novel coronavirus (COVID-19). For all coronavirus resources and news updates, visit our COVID-19 page.
Latest
The Centers for Disease Control and Prevention will award states and territories another $227 million in funding from the Coronavirus Aid, Relief, and Economic Security Act and Paycheck Protection Program and Health Care Enhancement Act for COVID-19 vaccine preparedness and complementary activities, the Department of Health and Human Services announced.
The Department of Health and Human Services announced that it has begun distributing $24.5 billion in “Phase 3” funds from the Public Health and Social Services Emergency Fund to eligible hospitals, as well as other providers.
Children and adolescents in Mississippi who tested positive for the SARS-CoV-2 virus were more likely to report close contact with someone with confirmed COVID-19 and less likely to report consistent mask use at school, according to a study released by the Centers for Disease Control and Prevention.
The AHA released a new edition of the COVID-19 Snapshot, highlighting the critical needs of hospitals and health systems during the deepening public health emergency.
The Food and Drug Administration issued an emergency use authorization for the first over-the-counter fully at-home diagnostic test for COVID-19. The antigen test for persons age 2 and older can detect the SARS-CoV-2 virus in a nasal swab sample in about 20 minutes.
Ahead of a Dec. 17 meeting of its Vaccines and Related Biological Products Advisory Committee, the Food and Drug Administration released a briefing document confirming Moderna’s data on the safety and efficacy of the mRNA-1273 COVID-19 vaccine candidate.
In an open letter, the AHA, American Medical Association and American Nurses Association thanked health care professionals for their dedication and sacrifices this year and urged them to continue their battle against COVID-19 by taking a vaccine and sharing their experience with others.
Combining the anti-inflammatory drug baricitinib with the antiviral drug remdesivir reduced the median recovery time for hospitalized COVID-19 patients from eight to seven days, according to clinical trial results published in the New England Journal of Medicine.
The Department of Health and Human Services Dec. 11 announced it would purchase from Moderna 100 million additional doses of its mRNA-1273 COVID-19 vaccine candidate.
Following the Food and Drug Administration’s Dec. 11 emergency use authorization of Pfizer, Inc.’s BNT162b2 mRNA COVID-19 vaccine, AHA released a Special Bulletin with important details for hospitals and health systems.
It was not at all the year I expected, and it certainly wasn’t the year any of us wanted. But, through it all, I continually found inspiration. Even now in the uncertainty of what 2021 will bring, I’m reassured knowing that no matter what, the teams who power our hospitals and health systems across America are continuing the fight against COVID-19.
A recent Centers for Disease Control and Prevention analysis based on 14 states found that the cumulative incidence of lab-confirmed COVID-19 cases among American Indian and Alaska Native persons was 3.5 times higher than among white persons, underscoring the need to develop collaborative approaches with federal, state, municipal and tribal agencies to minimize the impact of COVID-19 on these communities.
With the COVID-19 pandemic affecting some individuals and communities much more than others, population health tools are more important than ever.
The Food and Drug Administration authorized LabCorp’s Pixel COVID-19 Test Home Collection Kit for use by adults without a prescription.
The Centers for Medicare & Medicaid Services updated its FAQs regarding coverage, billing and payment for monoclonal antibody therapies used to treat COVID-19.
The Department of Defense announced a phased plan for the distribution and administration of initial and subsequent COVID-19 vaccine allocations to populations of DoD uniformed service members, including members of the National Guard; dependents; retirees; civilian employees; and select DoD contract personnel as authorized in accordance with agency regulation.
Peer-reviewed data for Pfizer Inc.’s BNT162b2 mRNA COVID-19 vaccine candidate was published by the New England Journal of Medicine, confirming its safety and efficacy.
The Department of Health and Human Services updated its guidance to hospitals on the reporting of COVID-19-related data.
This podcast, in support of AHA’s national strategic alliance with the National Urban League, is bringing attention to health inequities in Black and underserved communities through the lens of the ongoing COVID-19 public health emergency and this year’s flu season.